AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1977079 — intervention group
Group type: COMPARATOR
Intervention: Low-dose group (zidovudine 200 mg every four hours for four weeks, then 100 mg every four hours)
Number of subjects: 524
Study 1977079 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-treatment group
Number of subjects: 524
Study 1977079 — intervention group
Group type: COMPARATOR
Intervention: Low-dose group
Number of subjects: 524
Study 513673 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (planning and assessment training)
Number of subjects: 0
Study 513673 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (no planning and assessment training)
Number of subjects: 0
Study 30315130 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Cyclopentolate Hydrochloride for cycloplegic autorefraction
Number of subjects: 1626
Study 30315130 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity assessment with spectacles if worn
Number of subjects: 1626
Study 28697497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of aflibercept (IVA) 2.0 mg every 2 months after 3 initial monthly doses
Number of subjects: 50
Study 26448315 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐0 polypropylene running sutures
Number of subjects: 10
Study 26448315 — intervention group
Group type: COMPARATOR
Intervention: 1/4 Steri‐Strip films
Number of subjects: 10
Study 23884909 — intervention group
Group type: COMPARATOR
Intervention: Breath-hold technique
Number of subjects: 10
Study 23884909 — intervention group
Group type: EXPERIMENTAL
Intervention: Free breathing
Number of subjects: 10
Study 21728272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized Ipraterol
Number of subjects: 20
Study 21728272 — intervention group
Group type: COMPARATOR
Intervention: Nebulized Berodual
Number of subjects: 20
Study 19367283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomeguatrib (LM) with temozolomide (TMZ) for 5, 10 or 14 days
Number of subjects: 0
Study 19367283 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ) alone
Number of subjects: 0
Study 16926252 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) administration in men
Number of subjects: 104
Study 16926252 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone plus GH administration in men
Number of subjects: 104
Study 16926252 — intervention group
Group type: COMPARATOR
Intervention: GH alone in men
Number of subjects: 104
Study 16926252 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 104
Study 16926252 — intervention group
Group type: COMPARATOR
Intervention: Sex steroid(s) alone in women (estrogen/progesterone)
Number of subjects: 104
Study 16926252 — intervention group
Group type: COMPARATOR
Intervention: Sex steroid(s) combined with GH in women
Number of subjects: 104
Study 14741071 — intervention group
Group type: EXPERIMENTAL
Intervention: nateglinide 120 mg t.i.d. for 5 days
Number of subjects: 11
Study 14741071 — intervention group
Group type: COMPARATOR
Intervention: placebo for 5 days
Number of subjects: 11
Study 11533313 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 0
Study 11533313 — intervention group
Group type: COMPARATOR
Intervention: High protein intake
Number of subjects: 0
Study 11533313 — intervention group
Group type: COMPARATOR
Intervention: Individual amino acids
Number of subjects: 0
Study 9107259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of at least two drugs
Number of subjects: 0
Study 9107259 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution or addition of at least two new agents
Number of subjects: 0
Study 9107259 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load and CD4 measurements
Number of subjects: 0
Study 9107259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of two nucleoside analogues plus a third agent
Number of subjects: 0
Study 9107259 — intervention group
Group type: EXPERIMENTAL
Intervention: Two protease inhibitors
Number of subjects: 0
Study 9107259 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in viral load to below the detection level
Number of subjects: 0
Study 8322143 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine hydrochloride
Number of subjects: 0
Study 8322143 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 0
Study 3004189 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (500 mg cholesterol/day)
Number of subjects: 49
Study 3004189 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cholesterol diet (250 mg/day)
Number of subjects: 49
Study 3004189 — intervention group
Group type: EXPERIMENTAL
Intervention: Added-bran diet (30 g/day)
Number of subjects: 49
Study 3004189 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) oil (20% of fat)
Number of subjects: 49
Study 31952982 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate-lowering therapy (ULT) with Allopurinol
Number of subjects: 13
Study 31952982 — intervention group
Group type: COMPARATOR
Intervention: Preventive treatment of asymptomatic and non-severe hyperuricemia
Number of subjects: 13
Study 30333462 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR determination
Number of subjects: 140
Study 27141626 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia (IVA)
Number of subjects: 80
Study 27141626 — intervention group
Group type: COMPARATOR
Intervention: Forearm-injection (forearm-)
Number of subjects: 80
Study 27141626 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiaji (EX-B 2)-injection (EX-B 2-1)
Number of subjects: 80
Study 27141626 — intervention group
Group type: EXPERIMENTAL
Intervention: Zusanli-injection (ST 36-1)
Number of subjects: 80
Study 23844563 — intervention group
Group type: EXPERIMENTAL
Intervention: dAMB starting on day 4 (group A, n=27)
Number of subjects: 56
Study 23844563 — intervention group
Group type: COMPARATOR
Intervention: dAMB starting on day 8 (group B, n=29)
Number of subjects: 56
Study 23844563 — intervention group
Group type: EXPERIMENTAL
Intervention: dAMB starting on day 4 (group A)
Number of subjects: 56
Study 23844563 — intervention group
Group type: COMPARATOR
Intervention: dAMB starting on day 8 (group B)
Number of subjects: 56
Study 23844563 — intervention group
Group type: EXPERIMENTAL
Intervention: dAMB (both groups)
Number of subjects: 56
Study 21359666 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐min polysomnographically‐monitored sleep condition
Number of subjects: 85
Study 21359666 — intervention group
Group type: COMPARATOR
Intervention: No-sleep condition
Number of subjects: 85
Study 19804431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar)
Number of subjects: 0
Study 19804431 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 18772703 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hyperventilation (ETCO2 of 30 mm Hg)
Number of subjects: 19
Study 18772703 — intervention group
Group type: COMPARATOR
Intervention: Normal ventilation (ETCO2 of 40 mm Hg)
Number of subjects: 19
Study 15781530 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson-C MRB
Number of subjects: 10
Study 15781530 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson-C MRB at PEEP > 10 cm H(2)O
Number of subjects: 10
Study 15781530 — intervention group
Group type: COMPARATOR
Intervention: Laerdal MRB at PEEP > 10 cm H(2)O
Number of subjects: 10
Study 12610182 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy-to-read consent statement
Number of subjects: 207
Study 12610182 — intervention group
Group type: COMPARATOR
Intervention: Standard consent statement
Number of subjects: 207
Study 11599829 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous continuous ante‐ and retrograde cardioplegia
Number of subjects: 40
Study 11599829 — intervention group
Group type: COMPARATOR
Intervention: Continuous retrograde blood cardioplegia
Number of subjects: 40
Study 9306024 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 50
Study 9306024 — intervention group
Group type: COMPARATOR
Intervention: IUD
Number of subjects: 50
Study 8220405 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2941929 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms recombinant hepatitis B vaccine
Number of subjects: 54
Study 31541597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal PRP injection and excimer laser
Number of subjects: 52
Study 31541597 — intervention group
Group type: COMPARATOR
Intervention: Excimer laser only
Number of subjects: 52
Study 29738424 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estradiol tablet (10μg)
Number of subjects: 302
Study 29738424 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal moisturizer
Number of subjects: 302
Study 27238895 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy along with NSAIDs for 12 weeks
Number of subjects: 46
Study 27238895 — intervention group
Group type: COMPARATOR
Intervention: Placebo along with NSAIDs for 12 weeks
Number of subjects: 46
Study 24280856 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 questions
Number of subjects: 180
Study 24280856 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 questions
Number of subjects: 180
Study 24280856 — intervention group
Group type: COMPARATOR
Intervention: 0 questions
Number of subjects: 180
Study 24280856 — intervention group
Group type: COMPARATOR
Intervention: 1 question
Number of subjects: 180
Study 24280856 — intervention group
Group type: COMPARATOR
Intervention: 5 questions
Number of subjects: 180
Study 24280856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest included
Number of subjects: 180
Study 23834705 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered light (intervention)
Number of subjects: 9
Study 23834705 — intervention group
Group type: COMPARATOR
Intervention: Standard indoor light (baseline)
Number of subjects: 9
Study 19911245 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive subvastus approach
Number of subjects: 100
Study 19911245 — intervention group
Group type: COMPARATOR
Intervention: Conventional peripatellar approach
Number of subjects: 100
Study 18212713 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and strength training
Number of subjects: 82
Study 18212713 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 82
Study 16483967 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy in aCL positive primiparae (49 subjects)
Number of subjects: 924
Study 16483967 — intervention group
Group type: COMPARATOR
Intervention: aCL positive status
Number of subjects: 924
Study 14587042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent anti-D treatment
Number of subjects: 70
Study 14587042 — intervention group
Group type: COMPARATOR
Intervention: Routine care (glucocorticoid treatment followed by splenectomy)
Number of subjects: 70
Study 10807447 — intervention group
Group type: EXPERIMENTAL
Intervention: Single chamber atrial pacing (AAI)
Number of subjects: 30
Study 10807447 — intervention group
Group type: COMPARATOR
Intervention: Dual chamber pacing (DDD)
Number of subjects: 30
Study 10807447 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary AAI pacing (in DDD group)
Number of subjects: 30
Study 10807447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AAI and DDD pacing
Number of subjects: 30
Study 8635394 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II screening, randomized phase II studies, and multicenter, comparative, randomized phase III trials
Number of subjects: 0
Study 31558493 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal thickness at the apex
Number of subjects: 1383
Study 31558493 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal thickness at the entrance pupil centre
Number of subjects: 1383
Study 31558493 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal thickness at the thinnest point
Number of subjects: 1383
Study 31558493 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Pachymetric Progression Index (PPI)
Number of subjects: 1383
Study 31558493 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Ambrósio relational thickness (ART max)
Number of subjects: 1383
Study 29217387 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised duration of elastic compression therapy
Number of subjects: 865
Study 29217387 — intervention group
Group type: COMPARATOR
Intervention: Standard duration of elastic compression therapy (24 months)
Number of subjects: 865
Study 27099242 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical local anaesthesia
Number of subjects: 44
Study 27099242 — intervention group
Group type: COMPARATOR
Intervention: Water-based gel (placebo)
Number of subjects: 44
Study 25897826 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus rmhTNF (265 patients)
Number of subjects: 529
Study 25897826 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (264 patients)
Number of subjects: 529
Study 23629091 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 44
Study 23629091 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Number of subjects: 44
Study 21970923 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with electrical fields
Number of subjects: 0
Study 18573765 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterweight weight management programme
Number of subjects: 3400
Study 16060944 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 883
Study 16060944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 883
Study 11823767 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine initiation at 20 mg/d for 1 month
Number of subjects: 156
Study 11823767 — intervention group
Group type: COMPARATOR
Intervention: Usual care with telephone follow-up at 3 months
Number of subjects: 156
Study 11823767 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment continued for at least 1 month
Number of subjects: 156
Study 11823767 — intervention group
Group type: EXPERIMENTAL
Intervention: Any antipanic medication at 3 months
Number of subjects: 156
Study 10782562 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (generally 10 mg/day)
Number of subjects: 0
Study 8746920 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (2 mg daily)
Number of subjects: 150
Study 8746920 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg daily)
Number of subjects: 150
Study 8746920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 2390504 — intervention group
Group type: EXPERIMENTAL
Intervention: No. 1 polygalactide (Vicryl)
Number of subjects: 114
Study 2390504 — intervention group
Group type: COMPARATOR
Intervention: No. 1 chromic catgut
Number of subjects: 114
Study 6791054 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid after 10 weeks
Number of subjects: 7
Study 6791054 — intervention group
Group type: COMPARATOR
Intervention: Control and placebo periods
Number of subjects: 7
Study 31429207 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) at 40% of maximal inspiratory pressure (MIP) for 6 weeks
Number of subjects: 84
Study 31429207 — intervention group
Group type: COMPARATOR
Intervention: Sham Inspiratory Muscle Training at 10% of MIP for 6 weeks
Number of subjects: 84
Study 30615104 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding + Normal Sleep (8 h sleep opportunity time)
Number of subjects: 10
Study 30615104 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding + Sleep Restriction (4 h sleep opportunity time)
Number of subjects: 10
Study 28743313 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions
Number of subjects: 135
Study 28743313 — intervention group
Group type: COMPARATOR
Intervention: Attention control sessions
Number of subjects: 135
Study 25881382 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 56
Study 25881382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed tongue appliance
Number of subjects: 56
Study 23666554 — intervention group
Group type: COMPARATOR
Intervention: Benzylpiperazine (BZP) 200 mg
Number of subjects: 0
Study 23666554 — intervention group
Group type: COMPARATOR
Intervention: Trifluoromethylphenylpiperazine (TFMPP) 50 or 60 mg
Number of subjects: 0
Study 23666554 — intervention group
Group type: COMPARATOR
Intervention: Benzylpiperazine (BZP) 200 mg + Trifluoromethylphenylpiperazine (TFMPP) 100 mg + 30 mg
Number of subjects: 0
Study 23666554 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 21489843 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year interdisciplinary intervention including individual counseling every 6 weeks and 25 group seminars (group I; n=22)
Number of subjects: 48
Study 21489843 — intervention group
Group type: COMPARATOR
Intervention: Group intervention comprising seminars only (group G; n=26)
Number of subjects: 48
Study 21489843 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year interdisciplinary intervention (group I)
Number of subjects: 48
Study 21489843 — intervention group
Group type: COMPARATOR
Intervention: Group intervention (group G)
Number of subjects: 48
Study 21489843 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct cost of individual intervention
Number of subjects: 48
Study 19681868 — intervention group
Group type: EXPERIMENTAL
Intervention: Avizafone (20 mg)
Number of subjects: 0
Study 19681868 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (11.3 mg)
Number of subjects: 0
Study 19681868 — intervention group
Group type: EXPERIMENTAL
Intervention: Avizafone (20 mg) with atropine (2 mg) and pralidoxime (350 mg)
Number of subjects: 0
Study 16434092 — intervention group
Group type: EXPERIMENTAL
Intervention: Core‐Flo (Bisco Inc.)
Number of subjects: 40
Study 16434092 — intervention group
Group type: EXPERIMENTAL
Intervention: UniFil Core (GC Corp.)
Number of subjects: 40
Study 16434092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Ceram (Ivoclar‐Vivadent)
Number of subjects: 40
Study 16434092 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradia Direct (GC Corp.)
Number of subjects: 40
Study 16434092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisfil 2B (Bisco, Inc.)
Number of subjects: 40
Study 16434092 — intervention group
Group type: EXPERIMENTAL
Intervention: AEliteflo (Bisco, Inc.)
Number of subjects: 40
Study 16434092 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Flow (3M ESPE)
Number of subjects: 40
Study 16434092 — intervention group
Group type: EXPERIMENTAL
Intervention: UniFil Flow (GC Corp)
Number of subjects: 40
Study 14764127 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 1281
Study 14764127 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily
Number of subjects: 1281
Study 14764127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 1281
Study 14764127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1281
Study 11720430 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF alone (5 microg kg(‐1), bid, 14 consecutive days every 21 days)
Number of subjects: 32
Study 11720430 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF with dacarbazine (5 microg kg(‐1), bid, day 2 to day 19 every 21 days and DTIC: 800 mg m(‐2), day 1 of each cycle)
Number of subjects: 32
Study 11720430 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 32
Study 9164318 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral treatment (HAART) regimens
Number of subjects: 76
Study 9164318 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 76
Study 8483674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast task speed, immediate time estimates
Number of subjects: 60
Study 8483674 — intervention group
Group type: COMPARATOR
Intervention: Slow task speed, immediate time estimates
Number of subjects: 60
Study 8483674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast task speed, delayed time estimates
Number of subjects: 60
Study 8483674 — intervention group
Group type: COMPARATOR
Intervention: Slow task speed, delayed time estimates
Number of subjects: 60
Study 3667007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline suspension
Number of subjects: 0
Study 3667007 — intervention group
Group type: COMPARATOR
Intervention: Slow-release theophylline tablets
Number of subjects: 0
Study 26951607 — intervention group
Group type: EXPERIMENTAL
Intervention: Hate Crime Beliefs Scale (HCBS) - Negative Views sub-scale
Number of subjects: 403
Study 26951607 — intervention group
Group type: EXPERIMENTAL
Intervention: Hate Crime Beliefs Scale (HCBS) - Offender Punishment sub-scale
Number of subjects: 403
Study 26951607 — intervention group
Group type: EXPERIMENTAL
Intervention: Hate Crime Beliefs Scale (HCBS) - Deterrence sub-scale
Number of subjects: 403
Study 26951607 — intervention group
Group type: EXPERIMENTAL
Intervention: Hate Crime Beliefs Scale (HCBS) - Victim Harm sub-scale
Number of subjects: 403
Study 26951607 — intervention group
Group type: EXPERIMENTAL
Intervention: Political beliefs and prejudice measures
Number of subjects: 403
Study 28230262 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (5 g dose)
Number of subjects: 283
Study 28230262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 25523492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 45
Study 25523492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation sedation with nitrous oxide/oxygen (N2O/O2)
Number of subjects: 45
Study 25523492 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual behaviour management techniques)
Number of subjects: 45
Study 23478620 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Number of subjects: 341
Study 23478620 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-water irrigation
Number of subjects: 341
Study 23478620 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 341
Study 21953275 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg) taken with food
Number of subjects: 31
Study 21953275 — intervention group
Group type: COMPARATOR
Intervention: Selumetinib (75 mg) taken after fasting for at least 10 hours
Number of subjects: 31
Study 21953275 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyl-selumetinib (active metabolite)
Number of subjects: 31